DNA Stock: Ginkgo Bioworks Announces New Collaboration
Biotechnology specialist Ginkgo Bioworks (NYSE: DNA ) is seeing shares skyrocket today following an announcement of a potentially lucrative collaboration. Specifically, Ginkgo will partner with Syngenta, which is billed as a “leader in agricultural innovation.
Down 81% in 2024, Is Ginkgo Bioworks Stock Still a Buy?
Ginkgo Bioworks is scaling down its workforce and operating footprint. It's also aiming to restrict the scope of the services it offers.
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $0.32, representing a -1.51% change from its previous close.
Stay Away: Why Ginkgo Bioworks Stock Is Not for the Faint-Hearted
There's definitely a science to picking beaten-down gems in the stock market. If you get it wrong, you could lose a lot of money.
3 Biotech Stocks to Sell in July Before They Crash & Burn
The biotech segment is a relatively new sector that combines the fields of biology and technology. It integrates natural sciences from biology and engineering aspects from technology to develop products with meaningful applications in areas like medicine, agriculture, therapeutics, and more.
3 Biotech Stocks Turning DNA Dreams Into Dollars
When discussing biotechnology, many focus on medication based on biochemical compounds and their downstream effects. Yet several branches of medical genetics and therapeutics have begun to find novel ways to treat and prevent diseases through gene editing, protein manipulation and overall DNA repair.
3 Top-Rated Gene Editing Stocks Actually Making Money
Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9.
Ginkgo Bioworks Layoffs Expand to 400 Job Cuts
Ginkgo Bioworks (NYSE: DNA ) layoffs continue today with the cell programming company announcing additional job cuts. The latest update to the Ginkgo Bioworks layoffs reveals that the company is planning to cut at least 35% of its workers.
Why Ginkgo Bioworks Stock Is Sinking Today
Ginkgo Bioworks continued its slide from earlier in the week. The company is cutting 25% of its workforce.
Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts
Ginkgo Bioworks (NYSE: DNA ) layoffs are coming for 158 of the company's employees and more are on the way. Ginkgo Bioworks has revealed that it's going to be cutting 158 jobs as part of its effort to reduce its labor costs by 25%.
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability - - Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand - STONY BROOK, NY AND JUPITER, FL / ACCESSWIRE / June 20, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company (NASDAQ:MRVI) and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of the companies' previously announced Linea™ RNAP manufacturing scale-up agreement. The joint process development project resulted in an over 70% reduction in Linea RNAP manufacturing costs and the manufacture of a quantity of Linea RNAP sufficient to support Applied DNA's anticipated near-term demand for critical starting material for mRNA production.
Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing
Partnership Will Aid Physicians in Precision Prescribing Decisions Based on Applied DNA's TR8™ Pharmacogenomic (PGx) Test STONY BROOK, NY / ACCESSWIRE / June 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a global leader in PCR-based DNA technologies, today announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, LLC (ADCL), will utilize the GenXys Health Care Systems (GenXys) suite of clinical decision support software for interpretation and reporting of ADCL's New York State Department of Health-approved TR8™ pharmacogenomic (TR8 PGx) test. The partnership is designed to improve patient outcomes and reduce healthcare costs through a data-driven approach that relates an individual's genetic factors to potential responses to prescription drugs.
